Roth Capital Reiterates Neutral on Capricor Therapeutics, Raises Price Target to $10.5

Benzinga · 18h ago
Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Neutral and raises the price target from $7 to $10.5.